A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

GRAIL Inc. GRAL

Weak broader-coverage candidate · GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

On FrontierLab's discovery record since 2026-06-18 (15 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-22), not the curated Frontier signal.

⚡ Surfaced on a price move — momentum is where to look, not a buy signal. The move that surfaced this name does not make it a good entry.

⚠ Pump risk: parabolic/spike characteristics detected in the screen flags. Treat any positive grade with extra skepticism.

Key quality signals

Revenue growth (YoY)	23.1%
Gross margin	-10.8%
Gross profits / assets	-0.01
Rule of 40	-315.3
Net margin	-338.4%
Cash runway (months)	35.1
PEG	—
Price / sales	28

Quality checklist

~ Revenue growth — 23.1% (pass ≥ 20%)
✗ Gross profits / assets — -0.01 (pass ≥ 0.33)
✗ Gross margin — -10.8% (pass ≥ 60%)
~ Cash generation
✗ Share dilution — 23%

Fundamentals — snapshot as of 2026-09-22

Stage	Established
Share issuance (YoY)	23% · heavy issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-9.75
Burn multiple	1.8
Gross-margin trend (pts)	45.7
Cash / assets	0.3
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-06

Momentum context — a snapshot from 2026-09-22, not current

Price at surface	$107.97 (as of 2026-09-22)
52-week range	$41.5 – $118.84
% off 52-wk high	-9.1%
RSI (14)	81
Relative volume	3.5×

Risk flags

Burning cash — operating margin is negative.Thin gross margin — keeps little of each sales dollar (judge it against its industry).Heavy dilution (~23%/yr) — top-decile share issuers have historically underperformed.Parabolic one-day spike (+34%) in the last month — extreme single-day moves tend to mean-revert.Volume 3.5× normal alongside the move — attention-crowded names tend to reverse over the following weeks.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-09-22 (end-of-day). How grades are computed →